Document is current
Any future updates will be listed below
-
Authors
Palmqvist, Sebastian https://orcid.org/0000-0002-9267-1930
Tideman, Pontus
Cullen, Nicholas
Zetterberg, Henrik https://orcid.org/0000-0003-3930-4354
Blennow, Kaj https://orcid.org/0000-0002-1890-4193
,
Dage, Jeffery L. https://orcid.org/0000-0002-2192-1699
Stomrud, Erik
Janelidze, Shorena https://orcid.org/0000-0003-2869-8378
Mattsson-Carlgren, Niklas
Hansson, Oskar https://orcid.org/0000-0001-8467-7286
-
Funding
Funding for this research was provided by:
Vetenskapsrådet (2018-02052, 2016-00906)
Hjärnfonden (FO2020-0271)
Alzheimerfonden (AF-940046, AF-745911)
Knut och Alice Wallenbergs Stiftelse (2017-0383)
- License Information
-
More Information
Article History
Received: 22 December 2020
Accepted: 12 April 2021
First Online: 24 May 2021
Competing interests
: S.P. has served on the scientific advisory boards for Hoffman-La Roche and Geras Solutions. H.Z. has served on the scientific advisory boards for Denali, Roche Diagnostics, Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics and CogRx, has given lectures in symposia sponsored by Fujirebio, Alzecure and Biogen and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. K.B. has served as a consultant, on advisory boards or on the data monitoring committees for Abcam, Axon, Biogen, JOMDD/Shimadzu, Julius Clinical, Eli Lilly, MagQu, Novartis, Roche Diagnostics and Siemens Healthineers and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. J.L.D. is an employee of Eli Lilly and Company. O.H. has acquired research support (for the institution) from AVID Radiopharmaceuticals, Biogen, Eli Lilly, Eisai, GE Healthcare, Pfizer and Roche. In the past 2 years, O.H. has also received consultancy/speaker fees from AC Immune, Alzpath, Biogen, Cerveau and Roche. S.J., P.T., N.C., E.S. and N.M.-C. report no disclosures.
